Humasis Co

Humasis Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Humasis Co (205470.KQ) as of Nov 10, 2026 is -62.10 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -95.22 % — a change of -34.78% (higher).

FCF Conversion

-62.10 %

YoY

-34.78%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Humasis Co is 2025 -62.10 % . FCF Conversion Rate (FCF/EBITDA) of Humasis Co was 2024 -95.22 % . It decreases by -34.78% higher compared to the previous year.

The Humasis Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
203.72 KRW
Jan 1, 2019
180.02 KRW
Jan 1, 2020
-3.71 KRW
Jan 1, 2021
123.61 KRW
Jan 1, 2022
86.49 KRW
Jan 1, 2023
142.17 KRW
Jan 1, 2024
-95.22 KRW
Jan 1, 2025
-62.10 KRW
The Humasis Co FCF Conversion history
YEARFCF ConversionYoY
-62.10 %-34.78%
-95.22 %-166.98%
142.17 %+64.37%
86.49 %-30.03%
123.61 %-3,427.68%
-3.71 %-102.06%
180.02 %-11.63%
203.72 %+128.04%
89.34 %-34.62%
136.64 %+16.69%
117.09 %-109.57%
-1,223.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

FCF Conversion Rate (FCF/EBITDA) of Humasis Co is -62.10 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Humasis Co changed from -95.22 % to -62.10 %, representing a -34.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Humasis Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humasis Co

All Key Metrics — Humasis Co